Abstract:

Objective   To observe the clinical efficacy of recombinant human endostatin (endostar) combined with chemotherapy for advanced non-small lung cancer. Methods   96 eligible cases pathologically and cytologically confirmed of advanced non-small cell lung cancer accepted the therapy of endostar and chemotherapy (NP,TP and GP regimen). The efficacy, time to progression, survival time and adverse effect were analyzed. Results   96 patients treated with endostar and chemotherapy were administrated for 244 cycles, 2.5 cycles on average. The overall response rate was 36.8% (28/76) and the clinical benefit rate was 89.5% (68/76). The median TTP was 7.8 months and the median OS was 12.0 months. The administrated cycles of endostar and the efficacy after 2 cycles were independent prognostic factors of TTP. The administrated cycles of endostar and the Karnofsky score were independent prognostic factors of OS. Cardiovascular toxicity was found in 6.3% of the patients, and the toxicity rate of grade Ⅲ was 2.0%. Conclusion   The addition of endostar to a chemotherapy regimen results in improvement of TTP and OS, and it is safe and tolerable. Patients who accepted endostar for more than 2 cycles and have a Karnofsky score over 80 could obtain more benefit from it.

Key words: Recombinant human endostatin; Carcinoma, non-small-cell lung; Treatment efficacy